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Summary 
Expression of the macrophage mannose receptor is inhibited by interferon y (IFN-30, a T helper 
type 1 (Th-1)-derived lymphokine. Interleukin 4 (I1:4), a Th-2 lymphocyte product, upregulates 
major histocompatibility  class II antigen expression but inhibits inflammatory cytokine production 
by macrophages. We have studied the effect of Ib4 on expression of the macrophage mannose 
receptor (MMR) by elicited peritoneal macrophages. We found that recombinant murine Ib4 
enhances MMR surface expression (10-fold) and activity (15-fold), as measured by the respective 
binding and degradation of 12SI-mannose-bovine serum albumin. Polymerase  chain reaction 
analysis of cDNAs from purified primary macrophage populations revealed that MMR, but not 
lysozyme or tumor necrosis factor ~  mRNA levels were markedly increased by IL-4. The above 
effects were associated with morphologic changes. These data establish II-4 as a potent and sdective 
enhancer of murine MMR activity in vitro. IL-4 induces inflammatory macrophages to adopt 
an alternative activation phenotype, distinct from that induced by IFN-% characterized  by a 
high capacity for endocytic clearance of mannosylated ligands, enhanced (albeit restricted) MHC 
class II antigen expression,  and reduced proinflammatory cytokine secretion. 
T 
he macrophage mannose receptor (MMR) (previously 
called the mannosyl fucosyl receptor [MFR]) is an im- 
portant phagocytic receptor mediating the binding and in- 
gestion of micro-organisms with surface mannose residues 
and soluble mannose-containing glycoproteins. It is expressed 
on resident and elicited peritoneal macrophages and alveolar 
macrophages, not expressed on monocytes, and at low levels 
on Bacill~-Calmette-Guerin  (BCG)- or IFN-3~-activated  mac- 
rophages (1). Therefore, the MMR is a marker of the resi- 
dent and elicited, but not IFN-y-activated, macrophage pheno- 
type. MMR activity is increased by steroids and IFN-ol and 
-fl, and is inversely correlated with MHC class II antigen 
expression, which is induced on immunologically  stimulated 
macrophages and used as a marker of activation. 
ID4, predominantly produced by activated Th cells of the 
type  2  phenotype  and  non-B,  non-T,  FcER +  cells, has 
pleiotropic effects on a variety of immune and nonimmune 
cells. As it induces the expression of MHC class II antigen 
on B cells and monocytes, and enhances macrophage tumori- 
cidal activity, it has been described as a macrophage-activating 
factor (2). However, the tumoricidal activity is confined to 
selected target cell lines, and only HLA-DR and HLA-DP 
but not HLA-DQ MHC class II molecules are induced by 
ID4. In addition, IL-4 induces MHC class II antigen expres- 
sion on restricted macrophage populations. In contrast, IFN-3' 
induces all three class II molecules on most if not all macro- 
phages (3, 4). Furthermore, Ib4 inhibits the expression of 
pro-inflammatory cytokine genes such as I1:1, TNF, and I1:8, 
and synergizes with steroids to inhibit macrophage proinflam- 
matory activity (5-9). In addition, I1:4 inhibits superoxide 
anion release from PMA or zymosan-treated monocytes (10), 
although this effect depends critically on the particular mac- 
rophage source used and on the presence of other cytokines 
(11, 12). With the exception of MHC class II expression, 
the influence of I1:4 on macrophage immune function ap- 
pears to contrast the effect of IFN-% the typical product of 
Th-1 cells and NK cells. Here, the effect of IL-4 on MMR 
expression and activity is compared with the effect of IFN-% 
a known inhibitor of MMR activity.  We provide in vitro 
evidence that I1:4 greatly enhances MMR activity of murine 
peritoneal exudate macrophages. The potency and efficacy of 
I1:4 is unmatched by any other known MMR inducer, such 
as dexamethasone. The data, taken together with previous 
studies, indicate that ID4 induces elicited macrophages to adopt 
an alternative macrophage phenotype, with very high MMR 
activity, restricted MHC class II antigen expression, and re- 
duced proinflammatory cytokine secretion.  The potential 
pathophysiologic function of such a macrophage population 
is discussed. 
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Animals 
Adult male BALB/c mice were bred at the Sir William Dunn 
School of Pathology, University of Oxford. 
Media and Reagents 
RPMI was obtained from Gibco-Biocult Ltd. (Paisley, Scotland) 
FCS was obtained from Seralab UK Ltd. (Crawley Down, UK), 
and routinely heat inactivated for 30 min at 56~  Media were 
supplemented with 10% FCS, glutamine (2 raM), penicillin  (50 
U/ml), and streptomycin (50/~g/ml). Bio-Gel P100 (fine) was ob- 
tained from Bio-Rad Laboratories (Richmond, CA). Mannan (from 
Saccharomyces  cerevisiae)  was obtained from Sigma  Chemical Co. 
(St. Louis,  MO). 
Antibodies and Cytoteines 
11Bll, an Ib4-blocking rat mAb, was purified by Dr. A. McWil- 
liam in this laboratory from a hybridoma cell line (American Type 
Culture Collection, R.ockville, MD) obtained through Dr. W. E. 
Paul (National Institutes of Health, Bethesda, MD). 5C6, a mouse 
complement receptor (CR3)-blocking rat mAb was isolated  and 
purified by Dr. H. Rosen in our laboratory (13). Murine rlFN-3~ 
was a gift from Dr. F. Balkwill (Imperial Cancer Research Fund, 
London, UK), and murine rlL-4 was a gift from Dr. S. Gillis (Im- 
munex, Seattle,  WA). 
Cells 
Thioglycollate-elicited and biogel bead-elicited peritoneal mac- 
rophages were isolated 4-5 d after intraperitoneal injection as pre- 
viously described  (14). Cells  were  plated  at  3  x  105  macro- 
phages/weU in 24-well tissue culture plates. The cells were incubated 
for 1 h  at 37~  in a 5% CO2 incubator and then washed four 
times with PBS at 4~  to remove nonadherent cells. Thereafter, 
cells were treated as described in the figure legends. For RNA iso- 
lation, Biogel bead-dicited peritoneal macrophages (BgPM) were 
incubated in 10-cm polystyrene petri dishes  as before but left in 
RPMI with 10% FCS overnight. The cells became nonadherent 
and were easily washed offthe dishes. These cells were centrifuged 
and spun into a Percoll (Pharmacia Fine Chemicals, Piscataway, NJ) 
differential density gradient. The macrophage fraction (>99.5% 
pure by immunocytochemistry) was collected and replated before 
cytokine treatment. 
Macrophage Mannosyl Receptor (MMR) Assays 
These assays were performed as described previously (15) with 
modifications as indicated. Briefly, mannosylated BSA (E-Y Labora- 
tories, San Mateo, CA) was trace labeled with 125I-Na by a modi- 
fied chloramine-T method. Ligand was tested for TCA precipita- 
bility before use. 
Binding and Internalization  of Mannose-specific  Ligands.  Binding 
and internalization were assayed at saturating concentrations of 
ligand using trace-labeled  mannose-BSA  (saturation,  250 rig/m1 
ligand/5  x  105 MO) in the presence or absence of mannan  (5 
mg/ml) or 100-fold excess unlabeled mannose-BSA.  Binding was 
assayed after 1 h at 4~  and internalization was assayed after 20 
min at 37~  Cells were washed in ice-cold PBS with 10 mM so- 
dium azide.  Then, 500/~1 of 1 N  NaOH was  added to dissolve 
the cells and cell-associated  radioactivity measured in a Packard 
gamma spectrometer (Packard Instrument Co. Inc., Downers Grove, 
IL).  Results  were  expressed  as  nanograms  of  mannose-BSA 
specifically bound or taken up per 5  x  105 MO plated. 
Degradation of l2SI-Mannose-BSA  by MO.  This was measured by 
the  appearance  of TCA-soluble labeled  material in  the culture 
medium. Degradation of 12SI-mannose-BSA is detectable after an 
",,40-min incubation at 37~  and continues at a linear rate for sev- 
eral days ifMO are maintained in the continuous presence ofligand. 
Trace amounts of sterile ligand (•106  cpm in 10/~1) were added 
to monolayers of adherent MO populations. Cells were incubated 
for 16 h (unless otherwise indicated), and a 0.4-ml aliquot of medium 
was removed to microfuge tubes. TCA was added to a final con- 
centration of 10% (wt/vol), the tubes incubated on ice for 30 min, 
and then spun for 10 rain in a centrifuge. Supernatant (0.2 ml) 
was removed, and 5/~1 of potassium iodide (4 M) followed by 10 
/~1 of H202 were added to each aliquot, incubated for 10 rain at 
room temperature, followed by the addition of 0.8 ml of chloro- 
form. The mixture was vortexed vigorously, spun, and 100 #1 of 
the clear aqueous phase  was  assayed in a gamma counter. Cell- 
dependent, saturable degradation of l~I-mannose-BSA  per unit of 
time was calculated as a function of MO number. Cell-free blanks 
were used routinely. 
Reverse Transcription (RT)-PCR  Analysis 
106 cells, as described in the figure legends,  were washed once 
with PBS (4~  and lysed with RNAzol solution (Cinna/Biotecx 
Laboratories,  Friendswood, TX). Total RNA was isolated and re- 
verse transcribed by standard procedures using Moloney Murine 
Leukaemia Virus reverse transcriptase (British Research Laborato- 
ries/Gibco, Paisley, Scotland).  Dilutions of cDNA's corresponding 
to 20-cell equivalents were subjected  to PCR (annealing tempera- 
ture: 60~  [Mg  2+ ]  =  2.0 mM) for 30 cycles using the following 
oligonucleotide primers: MMR (unpublished sequence), 5': AAA 
CAC AGA CTG ACC CTT CCC; 3': GTT AGT GTA CCG CAC 
CCT CC; TNF (16), (5': TGG CAG AAG AGG CAC TCC CC; 
3': GAG GAG CAC GTA GTC GGG GC); and lysozyme (17), 
5': CTA TGG AGT CAG CCT GCC G; 3': CAT GCT CGA ATG 
CCT TGG GG. PCR products were subjected to agarose gel elec- 
trophoresis  and  vis.ualised by  ethidium  bromide  staining.  The 
specificity of each amplification was verified by restriction enzyme 
cleavage of the product at an internal site. 
Results 
The elicited macrophage population used in this study facili- 
tated  analysis  of the  morphological  effect  of the  various 
cytokine treatments.  These cells become rounded and rela- 
tively nonadherent  to tissue culture plastic after overnight 
incubation (Fig. 1 A). Striking morphologic changes occurred 
within  8  h  after addition  of Ib4.  After overnight culture, 
the cells became firmly adherent and spread out on the tissue 
culture plastic, as shown in Fig.  1 B. ParaUel cultures of the 
more widely used thioglycollate-elicited macrophage popu- 
lations were not useful in assessing such changes, since these 
cells remain tightly adherent to tissue culture plastic under 
the culture conditions used here. Our findings prompted fur- 
ther analysis of Ib4 modulation of the elicited macrophage 
phenotype. 
As shown in Fig.  2, optimal MMR  activity after a 48-h 
culture in recombinant murine Ib4 was "~15-fold higher than 
in untreated controls.  Half-maximal induction occurred at 
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cultured on tissue culture plastic. Cells were har- 
vested  and treated as described  in Materials and 
Methods. Control macrophages were rounded and 
loosely adherent (.4). After overnight incubation 
in the presence of II:4 (1 ng/ml), the macrophages 
became  tightly adherent and well spread  (B). 
an II.-4 concentration of <100 pg/ml. IFN-  7  decreased and 
dexamethasone increased MMR activity <2.5-fold. Table 1 
shows that maximal degradation activity occurs after 48 h, 
although increased activity was measurable after 8 h of IL-4 
(5 ng/ml) treatment. Addition of an anti-murine IL-4 mAb, 
11Bll,  completely prevented the enhanced MMR activity. 
The changes in surface MMR expression in response to IL-4 
(5 ng/ml) were assessed by high-affinity binding at 4~  in 
the presence of labeled ligand.  Data in Fig. 2 b show that 
saturable binding was increased '~,12-fold  compared with con- 
trol cultures. The apparent affinity of the receptor-ligand in- 
teraction is unaltered by the IL-4 treatment. Note that this 
analysis is relative to mock-treated  controls, since the valency 
of the mannose-BSA is not known and precludes precise mea- 
surement of the number of binding sites. Mannan or excess 
cold mannose-BSA  effectively  competed for binding and degra- 
dation of iodinated ligand. Two similar independent binding 
assays revealed an increase in maximum binding over control 
cells of 7- and 10-fold, respectively. In addition,  internaliza- 
tion of mannose-BSA, as assayed 20 min after the addition 
of 12SI-mannose-BSA  at 37~  was 10-fold enhanced by IL-4 
treatment (data not shown). 
MMR mRNA is present at only low levels and Northern 
blot analysis of  mRNA induction was not successful. There- 
fore, we did RT-PCR analysis of MMR mRNA levels. Fig. 
3 shows that I1.-4, in contrast to IFN-  7 or mock-treated  con- 
trol cells, increases MMR mRNA levels as assayed by the 
RT-PCR using murine MMR-specific oligonucleotides. The 
unpublished  sequence of a mouse MMR cDNA was kindly 
provided by Dr. Alan Ezekowitz (Harvard Medical School, 
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Figure  2.  (a) Degradation of 12Sl-mannose-BSA  by BgPM in response to increasing doses of murine rlL-4, IFN-% and dexamethasone  (Dex).  Cells 
were harvested and plated in equal numbers  per well as described in Materials and Methods.  Cells were incubated  in the continuous presence of IL-4, 
IFN-% or Dex for 48 h before the addition of l:SI-mannose-BSA (0.25/~g/ml). Specific TCA-soluble counts present  in the culture medium after 16 h 
in the continuous  presence of 12Sl-mannose-BSA  were used as a measure of ligand degradation  as detailed in Materials and Methods.  Nonspecific counts, 
as determined by the addition  of 100-fold excess of mannose-BSA, were always <15 % of the total.  The data shown are from three separate experiments 
done in duplicate.  (b) Binding curve of BgPM incubated  with increasing amounts of 12SI-mannose-BSA. BgPM were incubated  with or without IL-4 
(5 ng/ml), and 48 h  later  specific binding of t2SI-mannose-BSA was measured  as described in Materials  and Methods.  Nonlinear regression analysis 
of the data was performed using the Marquandt-Levenberg  equation (SigrnaPlot,  version 4; Jandel Scientific, Erkrath,  Germany).  The Ka for control 
and  IL-4-treated cells is similar, indicating  that differences in 12Sl-mannose-BSA  binding reveal changes in receptor  capacity rather than affinity. The 
data  shown represent  one of two similar experiments  done in duplicate. 
Boston, MA). The same IL.4- or IFN-y-treated BgPM cDNAs 
were analyzed for lysozyme and TNF mRNA levels.  Fig.  3 
(bottom) shows that IFN-y causes an increase in specific signal 
for TNF mRNA,  as previously reported. Lysozyme mRNA 
levels were relatively unaltered by the various treatments.  Note 
that the apparent decrease in lysozyme signal in lane 2 is likely 
to be due to underloading of the lane since no change in lyso- 
zyme  signal was seen in four independent  experiments,  all 
of which  showed a markedly enhanced MMR  signal in re- 
sponse to IL-4. Qualitatively similar results were obtained using 
Table  1.  Time  Course of the Effect of IL-4 on MMR  Activity 
Time in  culture  Mock  treated  IL-4  (5  ng/ml)  treated 
h 
8  14  _+  3  21  _+  7 
20  17  _+  4  211  _+  26 
48  23  +  9  349  _+  19 
72  28  _+  10  361  +  22 
16  +  11Bl1"  53  _+  8  56  _+  7 
Monolayers  of macrophages  were cultured in medium, containing 10% 
FCS,  for the time indicated  in  the presence  or absence of IL-4.  lZSI- 
Mannose-BSA (~0.4 #g/ml) was added for the last 4 h of the time course 
and the amount of ligand degraded was measured as described in Materi- 
als and Methods. Results reflect the mean  _+  SD of triplicate  wells and 
are expressed  as nanograms  of ligand degraded  per 5  x  10  s cells. 
" For this  time point,  the ligand was  added  for the entire incubation. 
11Bll is an  IL-4 blocking mAb. 
Fig,~ 3.  ExvressionofiMR, 
lysozyme, and TNF mRNA tran- 
scripts by IL-4-treated peritoneal 
macrophages.  Total  RNA from 
control,  IFN-q{ and Iir4-treated 
BgPM  was  reverse transcribed, 
and cDNA fragments  specific for 
MMR  (top), lysozyme  (middle), 
and TNF (bottom)  were amplified, 
as  described  in  Materials  and 
Methods.  Lane I, II.-4 treated (16 
h); lane 2, IL-4 treated (4 h); lane 
3, IFN-3~  treated (16 h); lane 4  = 
mock treated. 
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cDNA corresponding to between 1 and 50 cell equivalents. 
The PCR data showing I1:4-dependent increase in MMIL 
mRNA levels were confirmed by nuclease protection assays 
(data  not shown). 
Discussion 
Previously, macrophage activation has been defined in terms 
of microbicidal and tumoricidal activity. However, cytokines 
or growth factors may have apparently antagonistic effects 
depending on the particular micro-organism or cellular target 
used. Although I1:4 has been regarded as an activator of cer- 
tain macrophage functions, such as MHC class II expression 
(2), its effect on microbicidal and cytotoxic activity remains 
controversial. The effect of I1:4 on modulation of the MMR, 
long used as negative marker for the IFN-~/-activated macro- 
phage phenotype, is simple to measure at the protein and 
mRNA level, and does not depend on an additional stimulus 
or trigger. This distinguishes the use of MMR expression 
from other more complex assays of macrophage activation. 
We have demonstrated that II:4 potently enhances the ex- 
pression and activity of the MMtL (Fig. 2), an important en- 
docytic receptor known to mediate the binding and inges- 
tion of mannosylated  proteins and macromolecules. This effect 
was similarly demonstrated on thioglycollate-elicited macro- 
phages, another elicited but immunologically nonactivated 
macrophage population (data  not  shown).  The increased 
binding and activity are  associated with increased  MMR 
mRNA levels (Fig.  3).  The RT-PCtL analysis used here is 
qualitative and not quantitative, but further experiments using 
serial dilutions of input cDNA for PCIL indicate that 11:4- 
treated (48 h) BgPM contain at least eightfold higher levels 
of MMR mRNA molecules than control populations (not 
shown). Taken together, the data suggest II-4 increases MMR 
surface expression, at least in part, through increased receptor 
synthesis. Although not experimentally addressed in this paper, 
it is possible that I1:4 has a further influence on the efficiency 
of delivery and degradation of ligand within lysosomes, since 
II:4 enhanced degradation of ligand 15-fold, as compared with 
an increase of surface expression and internalization of 7-12- 
fold each. Further experiments are required to examine the 
effect of I1:4 on enhanced receptor recycling and lysosomal 
delivery and degradation of MMR ligands. The effect of Ib4 
in upregulating MMR plasma membrane activity is not a 
general phenomenon since I1:4 reduces transferrin receptor 
activity and CD14 expression (18). 
We conclude that low and possibly physiologic concentra- 
tions of I1:4 are able to induce recently recruited inflamma- 
tory macrophages to have maximal endocytic clearance ca- 
pacity for mannosylated ligands.  In contrast to the effect of 
IFN-3r on TNF expression, Ib4-treated cells remain unprimed 
with respect to proinflammatory cytokine (e.g.,  TNF) re- 
lease. In addition, these data suggest that I1:4 is a candidate 
regulator of MMR expression in specific tissue micro-environ- 
ments. Although maximal in vitro I1:4 stimulation induces 
at least 10-fold higher MMR activity than is present in resi- 
dent peritoneal macrophages, low doses of 11:4, such as those 
found within tissues, may maintain tissue macrophage MMR 
expression at high levels, for example on sub-sets of alveolar 
macrophages (19). Additional circumstantial evidence of an 
I1:4-1ike action on alveolar macrophages is their very low 
proinflammatory secretory activity, but further in situ studies 
are required to test this hypothesis. 
Other cytokines tested so far include TGF-B, IFN-ol and 
-13, TNF, II.-2, I1:6, GM-CSF, M-CSF, and II.-10, but these 
recombinant proteins have only modest or no effect on elicited 
macrophage MMR activity in comparison to I1:4 (unpub- 
lished observations). R~cently, monomeric IgG2a was reported 
to induce MMIL expression (20). However, the IgG2a effect 
was studied in relation to bone marrow-derived macrophage 
precursor maturation but not elicited monocyte/macrophage 
populations. Further, while IgG2a greatly enhanced the early 
expression of MMR on BMM in culture, the maximum level 
of MMR activity was not greater than mock-treated cells 
incubated under standard conditions for 7 d. The effects ob- 
served in this study were probably not due to IgG2a produc- 
tion by contaminating B cells, as we used highly purified mac- 
rophage populations. In addition, II.-4 enhances the release 
of IgG1 and IgE, but greatly inhibits the release of IgG2a, 
from activated  B cells (21). 
The contrasting roles of II~4 and IFN-3' on macrophage 
immune activation are reflected in their opposing effects on 
inflammatory cytokine expression and respiratory burst poten- 
tial, although both are able to enhance MHC class II antigen 
expression.  Previous studies have documented the priming 
and inhibitory effects of IFN-3~ and I1:4,  respectively,  on 
inflammatory cytokine release, and parallel experiments done 
in this laboratory using BgPM have demonstrated that while 
IFN-q( greatly enhanced PMA-triggered superoxide release, 
Ib4 had no effect (not shown). Taken together, these data 
indicate that helper lymphocyte expression of I1:4 at an inflam- 
matory focus will cause recruited macrophages to acquire an 
entirely different phagocytic receptor and secretory capability 
compared with macrophages classically activated by IFN-3' 
treatment or BCG infection. The MMIL, previously used as 
a marker for immunologicaUy nonactivated macrophages, may 
instead be a marker of an alternative Th-2 immunologically 
activated macrophage phenotype. Studies are in progress to 
further define the role of Th cell-derived cytokines in the 
modulation of macrophage function. 
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